<img src="https://ml-eu.globenewswire.com/Resource/Download/3411c2bd-01a5-4d06-ad90-4a6e168bad61?size=2" nborder="0" align="left" hspace="5" vspace="5" title="ITM_Logo_Claim_RGB_high-res.png" alt="ITM Isotope Technologies Munich SE"/>Garching / Munich, May 19, 2026 –– <a href="https://www.globenewswire.com/Tracker?data=JXuA7qZYfBgs2QQ3JY_r8juYs6PSwl1UuKIohmS-5aHuhBGjjGXEWY1OKevc7naxKuYAldx2fBop3X9-muOus1GGs_Yzhy63dYNWBILMCs7tIICbK77THEh0L61kmeNt" rel="nofollow" target="_blank" title="ITM Isotope Technologies Munich SE">ITM Isotope Technologies Munich SE</a> (ITM), a leading radiopharmaceutical biotech company, today announced that dosimetry data from its Phase 3 COMPETE trial will be provided in a poster presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held from May 30 - June 2, 2026 in Los Angeles, California. ITM will also host a satellite symposium on the evolution of SSTR-targeted radiopharmaceutical therapy. Poster Presentation Details Title: Accurate single-time-point dosimetry of [177Lu]Lu-edotreotide using non-linear mixed-effects modeling: results from the COMPETE Phase 3 trial Display Date and Location: May 31 – June 2 at the SNMMI Science Pavilion Satellite Symposium Details Title: ITM Dinner Symposium – The Evolution of SSTR‑Targeted Therapy – from Agonists to Antagonists and Emerging Radionuclides Objective: Discuss the evolution of SSTR‑targeted radiopharmaceutical therapy; spanning early approaches, current ¹⁷⁷Lu agonist therapies to next‑generation ligand biology and emerging radionuclides – linking today’s clinical practice with future therapeutic directions Speaker: Dr. Julia Fricke, MD, Clinic for Radiology and Nuclear Medicine at the University Hospital Basel, Switzerland Date: May 31, 2026, 6:30 PM - 7:30 PM PT Location: Petree Hall C, LA Convention Center, Los Angeles, CA During the conference, ITM will exhibit its innovative isotope portfolio, including Lutetium-177, Actinium-225 and Terbium-161. Attendees will have the opportunity to learn more about the company’s innovative radiopharmaceutical pipeline and its capabilities in the manufacturing and supply of radioisotopes at booth #1523. About the COMPETE Trial The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product pending review by the U.S. Food and Drug Administration (FDA) and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. It is also being evaluated in COMPOSE (NCT04919226), a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. <a href="https://www.globenewswire.com/Tracker?data=r_dD7thjPUUbYidEVueqlXocwdO2GO6sK-3Oyhh8yFHYmntRCKy9vF23VPjkdQq3WxcEP34f6IvaelzqvFrK8jlTYee0oBw60A9umtK5vLvR8JTJ81OHBApnGzLZCnun" rel="nofollow" target="_blank" title="www.itm-radiopharma.com">www.itm-radiopharma.com</a> ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: <a href="https://www.globenewswire.com/Tracker?data=_o6Bcl4foPw1J40nKHcwUqR48i8iE20U2sYgUVKsyUmo3ROrJfd6x4zwMHVBhGPwtSaXzyCPHQeIRLdkRmpRusUyNtKT_Tbe9G5R5vAzDn3fd_9DSgRxYMMp9DHb-tSSR2CV25yCV3pdMMSYAQmm1A==" rel="nofollow" target="_blank" title="communications@itm-radiopharma.com">communications@itm-radiopharma.com</a> Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: <a href="https://www.globenewswire.com/Tracker?data=tfSd7B3ic7L11-KH-H0Vh8rhf2yTFiyC5XiEMjxap-KTF3Fch-DIB9vf1Eb-km___vC-iAbDRgLWsLgSHc4PIL7XyhC1rTsD_bQr7Y944r7wviqni8HYnCchxqr3O4QI" rel="nofollow" target="_blank" title="investors@itm-radiopharma.com">investors@itm-radiopharma.com</a> 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=2vX50yS1i32AYkRvPyBOzVSO5XcnZht-UDJNUjoShbcipojhP3c9x1aqxX_OMb0lVyFNuOJEC2O8rcBi8ze1-HdpqSsVZNHV8sBfcdqM2OV8t7pCPZGRaD0vz2VCtCzkzogRCZcWvrW4JG-6WHr3RSuDRqzeTfos7KGJlX7S0_YPDSrcZDt8qVF950MEvSkJ9tKKX4k2PnkRoNFVxtq3btJRBWmNWIKjB6paC596vv_abQqfubRnErkLcAgV1Z6dUdENWTN80qe0q-M0_zY3w9SuWzf4oLyjjyAhRWu7ris=" title="ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium" rel="nofollow">ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/N2RlMjQ3MjUtN2YzYi00NWU0LTliN2YtYWQ1YzU4M2MwYjdjLTEyNTc0NzEtMjAyNi0wNS0xOS1lbg==/tiny/ITM-Isotope-Technologies-Munic.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn